These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34957158)

  • 41. [Procedure for the marketing authorization of an antibacterial agent].
    López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of orphan drug approval in the European Union.
    Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
    Eur J Clin Pharmacol; 2008 May; 64(5):545-52. PubMed ID: 18210097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use.
    Cilia M; Ruiz S; Richardson P; Salmonson T; Serracino-Inglott A; Wirth F; Borg JJ
    AAPS PharmSciTech; 2018 Feb; 19(2):489-511. PubMed ID: 29027130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A regulatory take on cannabis and cannabinoids for medicinal use in the European Union.
    Lipnik-Štangelj M; Razinger B
    Arh Hig Rada Toksikol; 2020 Mar; 71(1):12-18. PubMed ID: 32597142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [European Agency for the Evaluation of Medicinal Products: five years experience].
    Sauer F
    Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Critical review on the Environmental Risk Assessment of medicinal products for human use in the centralised procedure.
    Caneva L; Bonelli M; Papaluca-Amati M; Vidal JM
    Regul Toxicol Pharmacol; 2014 Apr; 68(3):312-6. PubMed ID: 24447908
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutual recognition in the European system: A blueprint for increasing access to medicines?
    Škrnjug I; Uzeirbegović S; Romčević ML; Tomić S; Meyer H; Conrad C
    Regul Toxicol Pharmacol; 2019 Aug; 106():270-277. PubMed ID: 31071381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Safety monitoring of cell-based medicinal products (CBMPs)].
    Funk MB; Frech M; Spranger R; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1239-46. PubMed ID: 26391098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic indications in oncology: emerging features and regulatory dynamics.
    Tafuri G; Leufkens HG; Laing R; Trotta F
    Eur J Cancer; 2010 Feb; 46(3):471-5. PubMed ID: 20056536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparing access to orphan medicinal products in Europe.
    Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
    Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation.
    Detela G; Lodge A
    Mol Ther Methods Clin Dev; 2019 Jun; 13():205-232. PubMed ID: 30815512
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The licensing of medicines in the UK.
    Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Approvals of drugs with uncertain benefit-risk profiles in Europe.
    Banzi R; Gerardi C; Bertele' V; Garattini S
    Eur J Intern Med; 2015 Oct; 26(8):572-84. PubMed ID: 26342723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. European Union directives and their effect on the registration and authorisation of anthroposophic and homeopathic medicines.
    Laso LR; Alfonso-Galán MT
    Med Law; 2009 Mar; 28(2):269-82. PubMed ID: 19705642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
    Buljovčić Z
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to care.
    Krendyukov A; Singhvi S; Green-Morrison Y; Zabransky M
    Front Oncol; 2022; 12():714516. PubMed ID: 36387084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does the EU's Paediatric Regulation work for new medicines for children in Denmark, Finland, Norway and Sweden? A cross-sectional study.
    Lepola P; Wang S; Tötterman AM; Gullberg N; Harboe KM; Kimland E
    BMJ Paediatr Open; 2020; 4(1):e000880. PubMed ID: 33437879
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.